18F-FDG PET/CT imaging is an important diagnostic tool for accurate staging and assessment of response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast carcinoma (LABC). However, 18F-FDG being non-specific marker, it also accumulates in inflammatory conditions, leading to false positive results. Angiogenesis, an essential characteristic for tumor development, intrusion and metastasis can be imaged using 68Ga-labeled RGD tripeptide. We here depict a series of clinically staged LABC patients who underwent both 68Ga-DOTA-RGD2 and 18F-FDG PET/CT imaging for staging and illustrate the similarities and significant differences between the two tracers.

131I scan plays a crucial role in the management of patients with differentiated thyroid cancer for the evaluation of remnant thyroid tissue, residual/recurrent metastatic disease, posttherapy tracer distribution, and response assessment to high-dose 131I therapy. Different causes secondary to physiological, pathological, and anatomical variations have been described for false-positive findings in the whole-body planar images. This case report of a patient of differentiated thyroid cancer with undocumented trauma to the left knee region a day before receiving the high-dose radioiodine therapy showed an interesting image finding of tracer uptake at unusual site in the posttherapy whole-body 131I scan.

No abstract

No abstract

Incidental detection of coronavirus disease-2019 (COVID-19) related lung changes in 18 F-FDG PET/CT of oncology patients have been increasingly reported. Most of the case reports/series stressed the retrospective diagnosis of COVID-19 with the help of 18 F-FDG PET/CT lung findings.In this case report, we introduce a different aspect of COVID-19 related lung changes in 18 F-FDG PET/CT, interfering with the evaluation of metastatic lung lesions in patients with renal cell carcinoma.